Matthew Allen Cromie
Director Técnico/Científico/I+D en Eleison Pharmaceuticals, Inc. .
Cargos activos de Matthew Allen Cromie
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Eleison Pharmaceuticals, Inc.
 Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ. | Director Técnico/Científico/I+D | - | - |
Historial de carrera de Matthew Allen Cromie
Antiguos cargos conocidos de Matthew Allen Cromie.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| Hengrui Therapeutics, Inc. | Corporate Officer/Principal | - | - |
| EMERGENT BIOSOLUTIONS INC. | Director Técnico/Científico/I+D | - | - |
Cornerstone Pharmaceuticals, Inc.
 Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Corporate Officer/Principal | - | - |
Formación de Matthew Allen Cromie.
| Northwestern University | Graduate Degree |
| Michigan Technological University | Undergraduate Degree |
Estadísticas
Internacional
| Estados Unidos | 7 |
Operativa
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 2 |
| Undergraduate Degree | 1 |
Sectorial
| Health Technology | 3 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| EMERGENT BIOSOLUTIONS INC. | Health Technology |
| Empresas privadas | 3 |
|---|---|
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Commercial Services |
| Hengrui Therapeutics, Inc. | |
Eleison Pharmaceuticals, Inc.
Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ. | Health Technology |
- Bolsa de valores
- Insiders
- Matthew Allen Cromie
- Experiencia
